Skip to main content

New top story from Time: FDA Panel Greenlights First Single-Shot COVID-19 Vaccine, from Johnson & Johnson

https://ift.tt/3pZf3dk

The U.S. Food and Drug Administration’s (FDA) vaccine advisory committee earlier today (Feb. 26) voted unanimously to recommend Johnson & Johnson’s COVID-19 vaccine for emergency use authorization. While the FDA isn’t obligated to follow the committee’s advice, it generally does.

At the end of a full day of review and discussion of the company’s shot, all 22 voting members of the committee agreed that the vaccine was safe and effective enough to be used by the public. It’s the third vaccine that the group of independent experts has recommended, following Pfizer-BioNTech and Moderna. Unlike the two previous vaccines, J&J’s is a single shot, and can be shipped and stored under refrigerated, not frozen conditions, as the other two require.

The single dosing played a part in the committee’s decision. Logistically, vaccinating people one time is much easier than asking them to return for a second dose. “This was a relatively easy call,” Dr. Eric Rubin, editor in chief of the New England Journal of Medicine and professor at Harvard T.H. Chan School of Public Health, who voted to recommend the shot said during the discussion. “[The vaccine] clearly gets way over the bar of safety and efficacy, and it’s a single-dose vaccine.”

The committee members reviewed data presented by Janssen Pharmaceuticals, the J&J arm that developed the vaccine, as well as FDA scientists’ review of that data. Janssen’s vaccine uses a different technology than Pfizer-BioNTech and Moderna, which both relied on a new platform involving mRNA. Janssen’s vaccine, on the other hand, is made with a weakened cold virus that can’t cause disease, manipulated so that it carries the genes for making one of the key proteins of SARS-CoV-2, the virus that causes COVID-19. Once that viral protein is introduced to the body, human immune cells learn to recognize it as foreign and launch attacks against it.

In Janssen’s primary vaccine study, involving nearly 44,000 people, a single dose was found to be 66% effective in protecting people from moderate to severe COVID-19 disease. It was slightly less effective in protecting against new variants of the virus—against one that was first identified in South Africa, it was around 57%. Still, that protection met the threshold of 50% efficacy set by the FDA for granting emergency use authorization.

Committee members raised questions about how much of the immune response to the COVID-19 virus might be blunted by a response mounted against the weakened cold virus used as the delivery vessel, a well known effect using this vaccine platform. Such vaccines are also potentially less effective when boosted with additional shots since the body becomes tolerant to the weakened virus vector. However, Dr. Johan Van Hoof, managing director of Janssen Vaccines and Prevention, noted that tests on the company’s HIV vaccine candidate using similar technology have shown that people boosted with additional shots years after the first continued to generate strong immune responses that didn’t seem to be significantly affected by the weakened virus vector.

Many committee members raised questions about the company’s data showing that the vaccine produced a slightly lower response in terms of antibody levels against the virus among people over age 60, especially those with underlying health conditions—a group particularly vulnerable to COVID-19. However, Janssen studies found that these people still did not develop severe COVID-19 disease or need hospitalization compared to people getting placebo. In fact, the vaccine was 85% effective in protecting people from severe disease and overall there were only 21 deaths among the 44,000 people studied; five occurring among those who were vaccinated and the remainder among the placebo group. None of the deaths were considered related to the vaccine.

The FDA scientists did note in their review that some participants in the study did experience serious side effects, including tinnitus (ringing in the ears), clotting and hives—which could be related to the vaccine and are worth further follow up. However, these were rare, and overall the vaccine was safe with most who reported side effects having only mild to moderate reactions including headache, chills and muscle aches.

The other question that continued to pop up during the day-long discussion focused on whether Janssen’s vaccine is really a one-shot vaccine or whether it, like the Pfizer-BioNTech and Moderna vaccines, actually requires a two-shot regimen. While the data the company submitted were from a trial in which participants were given only a single dose, the company is currently conducting another study of 30,000 people who will receive two doses of the shot—to see if an additional booster will raise immune responses even further.

If two doses prove to be more effective, it will raise a tricky question about what to do with people who might receive the single dose shot in coming weeks or months, should the one-dose regimen be authorized. Van Hoof argues that this is a question worth putting off for later, given the urgency of the current situation. “We feel the results of the study of our single dose showed high efficacy against severe disease, especially hospitalizations and death, and in a situation of mass vaccination programs, our regimen is extremely well positioned to be used during the outbreak,” he said.

Then of course there is the question of the recently identified genetic variants of SARS-CoV-2 that appear even more infectious than the original virus. Pfizer-BioNTech and Moderna did not have to deal with that when they submitted their requests back in December 2020, but the companies have since conducted additional tests that have shown that their vaccines remain effective in protecting against the major new mutations. Janssen’s submission to the FDA included some early data on the efficacy of its vaccine against the new variants, and Van Hoof told the committee that the company plans to continue genetic sequencing virus from people in the company’s trials if they test positive and will include that information in the final request for full approval which could come later this year. In the meanwhile, Janssen—like Pfizer-BioNtech and Moderna—is already working on a next-generation vaccine specifically targeting the new variants that could begin human testing by summer.

The FDA committee’s decision to recommend the Janssen shot now goes to the agency. If the FDA agrees to grant the emergency use authorization, the next step will be for the Centers for Disease Control and Prevention’s immunization committee to work out details of who should be vaccinated with the new shot, and the logistics for how to make that happen. That CDC committee will also likely make decisions about whether certain groups should be targeted to receive this specific vaccine, and what advice to provide vaccinators when people ask about whether they will need a second shot. That information won’t be available until Janssen completes its two-dose study in coming months.

Comments

Popular posts from this blog

Scientists uneasy as Russia approves 1st coronavirus vaccine https://ift.tt/3gOLOWL

Russia on Tuesday became the first country to approve a coronavirus vaccine, a move that was met with international skepticism and unease because the shots have only been studied in dozens of people.

सही पकड़े हैं - आपकी अंगूरी भाभी शुभांगी अत्रे को मिल गया है बिग बॉस 14 का न्योता

भाभी जी घर पर हैं, फैन्स के फेवरिट धारावाहिकों में से एक है और इसकी किरदार अंगूरी भाभी तो घर घर में चर्चित हैं। अब आपकी अंगूरी भाभी यानि कि शुभांगी अत्रे को बिग बॉस के घर में बंद होने का from टेलीविजन की खबरें | Television News in Hindi | TV Serials Update in Hindi – FilmiBeat Hindi http:/hindi.filmibeat.com/television/bhabhi-ji-ghar-par-hain-angoori-bhabhi-shubhangi-atre-approached-for-bigg-boss-14-090111.html?utm_source=/rss/filmibeat-hindi-television-fb.xml&utm_medium=104.71.130.47&utm_campaign=client-rss

Over dozen shops gutted in fire in Greater Noida market https://ift.tt/2Di1kfv

Around a dozen shops were gutted after a fire broke out at a market in Greater Noida (West) area of Uttar Pradesh's Gautam Buddh Nagar on Thursday night, officials said. The fire is suspected to have started around 8.30 pm with a short circuit in a home appliances shop and then spread to other outlets in the market, located in Bisrakh police station area, the officials said.

New top story from Time: Joe Biden Is Getting His Booster Shot Today

https://ift.tt/3ALygVX WASHINGTON — President Joe Biden will receive his COVID-19 booster shot on Monday, days after federal regulators recommended a third dose of the Pfizer vaccine for Americans age 65 or older and approved them for others with preexisting medical conditions and high-risk work environments. The White House said Biden, 78, would deliver remarks and receive the additional dose at 1 p.m. Monday. Biden got his first shot on Dec. 21 and his second dose three weeks later, on Jan. 11, along with his wife, Jill Biden. It was not immediately clear whether the first lady would also receive the booster dose on Monday. Speaking on Friday after the Centers for Disease Control and Prevention and the Food and Drug Administration authorized the Pfizer booster, Biden told reporters, “I’ll be getting my booster shot. It’s hard to acknowledge I’m over 65, but I’ll be getting my booster shot. ” Vice President Kamala Harris, 56, received the Moderna vaccine, for which feder...

Fire breaks out at shopping centre at Mumbai's Borivali West; efforts to douse flames on https://ift.tt/3iORMZb

A fire was reported at Mumbai's Borivali West early on Saturday. Nearly 14 fire tenders are present at the spot as the efforts to douse the flames continue.  from IndiaTV: Google News Feed https://ift.tt/2W9DhW9

New top story from Time: Tropical Storm Zeta Expected to Hit U.S. Gulf Coast by Midweek

https://ift.tt/2J1aWNX (MIAMI) — A strengthening Tropical Storm Zeta is expected to become a hurricane Monday as it heads toward the eastern end of Mexico’s resort-dotted Yucatan Peninsula and then likely move on for a possible landfall on the central U.S. Gulf Coast at midweek. Zeta, which on Sunday became the earliest ever 27th named storm of the Atlantic season, was centered about 260 miles (420 kilometers) southeast of Cozumel island late Sunday, the U.S. National Hurricane Center said. It had maximum sustained winds of 60 mph (95 kph). Though nearly stationary, the storm was expected to begin advancing on a path that would take it over the Yucatan Peninsula late Monday. It would then head into the Gulf of Mexico and approach the U.S. Gulf Coast by Wednesday, though it could weaken by then, the hurricane center said. Officials in Quintana Roo state, the location of Cancun and other resorts, said they were watching the storm. They reported nearly 60,000 tourists in th...

New top story from Time: Report: Homicides Continue to Slowly Rise in the U.S., While Other Violent Crimes Declines

https://ift.tt/3yp5v05 A new report from the Council on Criminal Justice (CCJ) presents data showing that murders have risen 16% in many major American cities over the first 6 months of 2021, as part of what is being widely viewed as a new wave of crime and violence across the U.S. But according to the report, when compared to the same time period last year, the pace of the increase in murders has slowed down from the first quarter of 2021 through the second: In the first quarter of 2021, homicides rose by 23% compared to last year. In the second quarter, they rose by just 10%. [time-brightcove not-tgx=”true”] By the numbers , these Q1/Q2 percentile rises represent 47 murders reported in Portland, Ore. in the first half of 2021 (versus 11 in the equivalent period of 2020), Houston with 228 murders (versus 173 in 2020) and Buffalo, N.Y. with 46 (versus 31 in 2020). But cities like St. Louis saw drops from 156 murders in the first half of 2020 to 108 so far this year, and Bos...

New top story from Time: Biden Laid Out an Ambitious Global Agenda at the UN General Assembly. Here’s How It Compares to Reality

https://ift.tt/3CJXKnj Everything is easier said than done, and that’s especially true for big challenges. Like, for example, trying to establish America’s place in the 21st century world—or persuading other governments to place their confidence in you. But no matter how tall the tasks, we shouldn’t dismiss a presidential speech at the United Nations as only hot air. With that in mind, let’s look closely at President Biden’s first address to the United Nations General Assembly (UNGA) this week and compare it with the choices the Biden administration has actually made. The agenda Biden laid out at the U.N. was plenty ambitious. His priorities are “ending this pandemic; addressing the climate crisis; managing the shifts in global power dynamics; shaping the rules of the world on vital issues like trade, cyber, and emerging technologies; and facing the threat of terrorism as it stands today.” Does he mean what he says? [time-brightcove not-tgx=”true”] COVID-19 Biden has ple...

New top story from Time: New Documents Reveal the Bloody Origins of America’s Long War on Drugs

https://ift.tt/3sJ25mR Over fifty years ago on June 17, 1971, President Richard Nixon declared to the Washington press corps that America had a new enemy—narcotics. “America’s public enemy number one,” Nixon claimed, “is drug abuse.” To fight it, it was necessary “to wage a new, all-out offensive.” Within days, U.S. newspapers took up the metaphor. The U.S. was now engaged in a “war on drugs.” Nixon’s speech marked the beginning of a new era of American drug policy. His announcement would lead to the mass imprisonment of domestic drug users from the 1980s onwards. But the real effect of Nixon’s speech occurred abroad. Here, rhetoric became reality; metaphor got real. Nixon’s speech let drug cops off the leash. And it sparked off a wave of extreme violence, which many drug producing countries in Central and Latin America are still living with today. [time-brightcove not-tgx=”true”] Nowhere was this militarization of the drug effort felt more than in Mexico. By the end of the...

FOX NEWS: Bride's father asks stepdad to help walk her down the aisle in sweet viral moment A selfless gesture by the father of a bride was shared on social media in a viral moment of him surprising the girl’s stepfather by asking him to help walk her to the altar.

Bride's father asks stepdad to help walk her down the aisle in sweet viral moment A selfless gesture by the father of a bride was shared on social media in a viral moment of him surprising the girl’s stepfather by asking him to help walk her to the altar. via FOX NEWS https://ift.tt/YysR7TE